NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its lead candidate NV-CoV-2 and enhanced liquidity measures positioning the company for future clinical trials and market expansion.
Financially, NanoViricides (NYSE-A:NNVC) reported a cash and cash equivalent current assets balance of approximately $5.31 million as of December 31, 2023, with additional agreements providing approximately $2.5 million available cash, totaling around $7.8 million cash available to the company.
In its filing with the SEC, NanoViricides highlighted its strong P&E assets, which include a cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $0.95 million.
Its lead drug candidate, NV-CoV-2, is being advanced into Phase I/II human clinical trials for the treatment of COVID-19.
Meanwhile, as clinical trials for NV-CoV-2, NanoViricides' lead drug candidate, progress, the cash expenditure rate is expected to increase. NV-CoV-2 is a unique, ultra-broad-spectrum antiviral nanomedicine designed to treat various viral infections, including SARS-CoV-2 (COVID-19), RSV infections, and Poxvirus infections.
To improve cash flow, NanoViricides said its Board has requested changes to milestone payments clauses, aiming to link cash awards to revenue generated from product operations.
Additionally, the company's largest shareholder, TheraCour Pharma, converted convertible promissory notes into preferred stock, enhancing the near-term liquidity outlook.
The Phase 1a/1b Human Clinical Trial of NV-CoV-2 demonstrated strong safety and tolerability, paving the way for further clinical trials. NanoViricides believes NV-CoV-2 formulations may be eligible for Phase II/III trials for various indications, including RSV and Poxvirus infections.
NanoViricides' platform technology, designed to mimic cell receptors used by viruses, offers a significant advantage in preventing viral escape. The company has also expanded its manufacturing capacity to support upcoming clinical trials.
Connecticut-based NanoViricides is a development stage company focused on creating nanomaterials for antiviral therapy.